TY - CHAP M1 - Book, Section TI - HIV Infection & AIDS: Prevention A1 - Gandhi, Monica A1 - Spinelli, Matthew A. A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. A2 - Gandhi, Monica PY - 2024 T2 - Current Medical Diagnosis & Treatment 2024 AB - Key Clinical Updates in Primary PreventionFor men who have sex with men and have creatinine clearance less than 60 mL/min but greater than 30 mL/min, or osteoporosis/osteopenia (or at risk for these conditions), clinicians may opt to use TAF/FTC or injectable cabotegravir PrEP. Oral lead-in dosing of cabotegravir prior to injection should be considered optional, as breakthrough seroconversions occurred during the oral lead-in period in one of the cabotegravir studies, and injectable cabotegravir is well tolerated. When using injectable cabotegravir, the most sensitive HIV testing available should be used. After discontinuation and with ongoing risk of HIV, the cabotegravir tail should be covered with TDF/FTC or TAF/FTC, with quarterly HIV RNA testing performed.Landovitz RJ et al; HPTN 083 Study Team. N Engl J Med. [PMID: 34379922] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/11/06 UR - accessmedicine.mhmedical.com/content.aspx?aid=1202072498 ER -